Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III placebo-controlled double-blind study of ME2112 (ziprasidone) in acute exacerbation of schizophrenia
jRCT2080222769Phase 3Completed
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ziprasidone in schizophrenia (4 arms), sponsored by Meiji Seika Pharma Co., Ltd. Started Feb 2015; status: completed.
02
Drugs
ziprasidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on jRCT2080222769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222769.